Skip to main content
BrainCited
Figure 1

More Figures from This Paper

Figure 3

Figure 3
Figure 4

Figure 4
Figure 5

Figure 5

Figure 1

720 × 538px · 240,9 KB

Source Paper

Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amyloid-β Antibodies and ω-3 Not Working in Clinical Trials?

Journal of Alzheimer's disease : JAD (2018)

PMID: 29103035

DOI: 10.3233/JAD-170579

Cite This Figure

![Figure 1: Figure 1](https://pdfs.citedhealth.com/figures/29103035/48.png)

> Source: Milan Fiala et al. "Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amylo." *Journal of Alzheimer's disease : JAD*, 2018. PMID: [29103035](https://pubmed.ncbi.nlm.nih.gov/29103035/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/29103035/48.png" alt="Figure 1" />
  <figcaption>Figure 1. Figure 1<br>  Source: Milan Fiala et al. "Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amylo." <em>Journal of Alzheimer's disease : JAD</em>, 2018. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29103035/">29103035</a></figcaption>
</figure>

Evidenze correlate

B
Omega-3 Fatty Acids (DHA/EPA) per Mild Cognitive Impairment (MCI)

Grado B · 18 studi